Immunocore Holdings annual free cash flow per share
2021
2022
2023
2024
2025
Immunocore Holdings Free Cash Flow Per Share Growth & History (IMCR)
Immunocore Holdings's free cash flow per share was -$0.30 for fiscal 2025.
View full Immunocore Holdings company overviewImmunocore Holdings annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$0.30 | -$0.72 | — |
| 2024 | 2024-12-31 | $0.42 | $0.47 | — |
| 2023 | 2023-12-31 | -$0.05 | $1.07 | — |
| 2022 | 2022-12-31 | -$1.12 | $2.28 | — |
| 2021 | 2021-12-31 | -$3.40 | — | — |
Immunocore Holdings quarterly free cash flow per share
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.30 | -$0.21 | −41.53% |
| Q1 2026 | 2026-03-31 | -$0.31 | -$0.31 | — |
| Q4 2025 | 2025-12-31 | -$0.70 | — | — |
| Q3 2025 | 2025-09-30 | -$0.10 | -$0.51 | — |
| Q2 2025 | 2025-06-30 | $0.51 | $0.05 | +9.80% |
| Q1 2025 | 2025-03-31 | $0.00 | $0.10 | — |
| Q3 2024 | 2024-09-30 | $0.41 | $0.20 | +101.87% |
| Q2 2024 | 2024-06-30 | $0.46 | $0.49 | — |
| Q1 2024 | 2024-03-31 | -$0.10 | -$0.26 | — |
| Q3 2023 | 2023-09-30 | $0.20 | — | — |
| Q2 2023 | 2023-06-30 | -$0.03 | — | — |
| Q1 2023 | 2023-03-31 | $0.16 | — | — |
Immunocore Holdings free cash flow per share trends
Between the periods ended 2021-12-31 and 2025-12-31, Immunocore Holdings's free cash flow per share increased from -$3.40 to -$0.30, a change of $3.10. The latest reported quarter, Q2 2026, shows $0.30.
About the metric
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
Calculation and source
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunocore Holdings source filings ↗